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Signal transductionLittle is known about the molecular mechanisms by which STAT proteins promote tumorigenesis. Drosophila
is an ideal system for investigating this issue, as there is a single STAT (Stat92E), and its hyperactivation
causes overgrowths resembling human tumors. Here we report the ﬁrst identiﬁcation of a dominant-active
Stat92E protein, Stat92EΔNΔC, which lacks both N- and C-termini. Mis-expression of Stat92EΔNΔC in vivo
causes melanotic tumors, while in vitro it transactivates a Stat92E-luciferase reporter in the absence of
stimulation. These gain-of-function phenotypes require phosphorylation of Y711 and dimer formation with
full-length Stat92E. Furthermore, a single point mutation, an R442P substitution in the DNA-binding domain,
abolishes Stat92E function. Recombinant Stat92ER442P translocates to the nucleus following activation but
fails to function in all assays tested. Interestingly, R442 is conserved in most STATs in higher organisms,
suggesting conservation of function. Modeling of Stat92E indicates that R442 may contact the minor groove of
DNA via invariant TC bases in the consensus binding element bound by all STAT proteins. We conclude that
the N- and C- termini function unexpectedly in negatively regulating Stat92E activity, possibly by decreasing
dimer dephosphorylation or increasing stability of DNA interaction, and that Stat92ER442 has a nuclear
function by altering dimer:DNA binding.New York University School of
0016-6402 USA. Fax: +1 212
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The Janus Kinase/Signal Transducer and Activator of Transcription
(JAK/STAT) pathway is evolutionarily conserved and is critical for
numerous biological processes, including immunity and proliferation
(reviewed in (Arbouzova and Zeidler, 2006; Levy and Darnell, 2002)).
STATs are a family of latent cytoslic transcription factors that are
activated by tyrosine phosphorylation, which allows the formation of
an activated dimer through reciprocal phosphorylated tyrosine-Src
Homology 2 (SH2) interactions between two STATmonomers. Studies
in cultured cells have led to a model in which JAK non-receptor
tyrosine kinases, constitutively associated with transmembrane
receptors, are activated following ligand binding (Fig. 1A). JAK
activation leads to the subsequent tyrosine phosphorylation of
receptor sites to which unphosphorylated STAT dimers dock. STAT
dimers are activated by JAK-dependent tyrosine phosophorylation
and are then able to bind to consensus sequences in target genes and
inﬂuence their transcription (Becker et al., 1998; Braunstein et al.,
2003; Chen et al., 2003; Chen et al., 1998; Kretzschmar et al., 2004;
Mao et al., 2005; Neculai et al., 2005; Novak et al., 1998; Schroder etal., 2004; Stancato et al., 1996). The activity of phosphorylated STAT
dimers is transient, and these dimers are dephosphorylated in the
nucleus and are exported to the cytoplasm (Mertens et al., 2006;
Reich and Liu, 2006; Zhong et al., 2005).
Mammals have seven STAT proteins (STAT1-4, 5a, 5b, and 6) that
share a similar conserved domain structure, including N-terminus,
coiled-coil, DNA-binding, linker, SH2, and C-terminus (Fig. 1B and
(Becker et al., 1998; Chen et al., 1998; Vinkemeier et al., 1998)). The
N-terminal domain (residues ∼1-130) is required for formation of
tetramers as well as of non-phosphorylated dimers, for tyrosine
dephosphorylation, for transcriptional activation and for protein-
protein interactions (Chang et al., 2003; Chen et al., 2003; Murphy et
al., 2000; Ota et al., 2004; Shuai et al., 1996; Vinkemeier et al., 1998;
Xu et al., 1996). A helical coiled-coil domain beginning around residue
130 mediates interaction between several proteins including c-Jun
(Zhang et al., 1999). The DNA-binding domain of STATs (DBD)
(residues ∼320 to 490) has limited contact with both the major and
minor grooves of DNA (Chen et al., 1998). The linker domain (residues
∼490 to 580) modulates the rate of STAT:DNA interactions, ultimately
controlling transcriptional activation of STAT target genes (Yang et al.,
2002). An SH2 domain (residues ∼580-680) is required for the
formation of an activated STAT dimer by mediating reciprocal
interactions with a phosphorylated conserved tyrosine residue at
position ∼700 that exists in all STATs (Chen et al., 1998; Levy and
Darnell, 2002). The phosphorylation of this tyrosine residue is
Fig. 1. Model of the Drosophila JAK/STAT pathway and Stat92E transgenes. (A) Model of the Drosophila JAK/STAT pathway. Hop is constitutively associated with Dome and is
activated by Upd binding to a dimerized form of Dome (Brown et al., 2003). Activated Hop subsequently phosphorylates one or more tyrosine residues in the Dome cytoplasmic
domain. Inactive Stat92E dimers dock at the phospho-tyrosine residues on the receptor. Stat92E dimers are then phosphorylated by the activated Hop proteins, assume an activated
dimer conformation and translocate to the nucleus where they inﬂuence the transcription of target genes. Subsequently, activated Stat92E dimers no longer bind to Stat92E binding
sites on DNA; they are dephosphorylated by an unidentiﬁed nuclear tyrosine phophatase (green Y-PPT); they are then exported as unphosphorylated inactive dimers to the
cytoplasm. The basal phosphorylation of Dome, Hop and/or Stat92E is balanced by the actions of cytoplasmic tyrosine phosphatases (orange Y-PPT). (B) Stat92E domains include an
N-terminal (N) (red), a coiled-coil (CC) (royal blue), a DNA binding (DBD) (yellow), a linker (L) (green), an SH2 (pink), and a C-terminal trans-activation (TAD) (turquoise). The
critical tyrosine in Stat92E is located at residue 711. Deletions and substitutions were made to a UAS-3HA-Stat92EFL transgene containing three N-terminal HA tags (purple).
Constructs include deletion of residues 1-133 (ΔN); 725-761 (ΔC); 1-133 and 725-761 simultaneously (ΔNΔC). Substitution constructs include a mutation of the critical Y711 to F in
ΔNΔC (ΔNΔCY711F); of R442 to P (R442P), R442 to K (R442K) and R442 to A (R442A); of the critical Y711 to F (Y711F). Constructs were tested in two Stat92Emutant backgrounds:
Stat92E85C9, which results from an R442P substitution, and Stat92E397, which results from a premature stop atW594. “Rescue” refers to the abilty of a Stat92E variant to rescue Stat92E
loss-of-function phenotypes in vivo. “Oncogenic” refers to the abilty of a Stat92E variant to cause overgrowths or melanotic tumors in vivo. Y=yes and N=no.
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in all species tested (Levy and Darnell, 2002). Lastly, the carboxy-
terminal transactivation domain (TAD) varies in length from 38 to 200
amino acids and is required for transcriptional co-activation of
mammalian STATs (Horvath, 2000).
Gain-of-function mutations in the Drosophila JAK hopscotch (hop)
were the ﬁrst to link the JAK/STAT pathway to cancer. These hop
alleles result in hyperactive kinases that cause an over-proliferation ofblood cells, leading to ﬂy “leukemia” and lethality (Binari and
Perrimon, 1994; Hanratty and Dearolf, 1993; Harrison et al., 1995;
Luo et al., 1995). Similarly, sustained activation of the JAK/STAT
pathway is a causal event in human leukemia and myeloproliferative
disorders (Baxter et al., 2005; James et al., 2005; Jones et al., 2009;
Kilpivaara et al., 2009; Lacronique et al., 1997; Levine et al., 2005;
Olcaydu et al., 2009). Persistent activation of Stat3 is associated with a
dozen types of human cancer, including all classes of carcinoma
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Stat3-C, generated by conversion of two residues in the C-terminal
loops of the SH2 domain to Cys, is oncogenic and causes tumors in
nude mice (Bromberg et al., 1999). The constitutive transcriptional
abilities of Stat3-C require tyrosine phosphorylation of Y705 and likely
arise because the cysteine mutations increase occupancy of the STAT
dimer on DNA and/or prevent its dephosphorylation, which results in
the accumulation of activated STAT dimers (Li and Shaw, 2006; Liddle
et al., 2006). Inhibition of Stat3 arrests the growth of primary human
cancer cells, which makes Stat3 an attractive target for cancer therapy
(Blaskovich et al., 2003; Chiarle et al., 2005; Song et al., 2005; Sun et
al., 2005).
Redundancy in components of the mammalian JAK/STAT path-
way exists at each level of this signaling cascade. In contrast, the
Drosophila pathway is a complete yet simpliﬁed version of its
mammalian counterpart (Arbouzova and Zeidler, 2006). Three
related IL-6-like cytokines, Unpaired (Upd), Upd2 and Upd3, activate
a gp-130-like receptor Domeless (Dome), which leads to the
activation of the sole JAK Hop and the sole STAT Stat92E (Fig. 1A
and (Agaisse et al., 2003; Binari and Perrimon, 1994; Brown et al.,
2001; Chen et al., 2002; Gilbert et al., 2005; Harrison et al., 1998;
Hombria et al., 2005; Hou et al., 1996; Sefton et al., 2000; Yan et al.,
1996)). Activated Stat92E regulates expression of target genes, such
as Socs36E, which encodes a negative regulator of the pathway
(Callus and Mathey-Prevot, 2002; Issigonis et al., 2009; Karsten et
al., 2002; Rawlings et al., 2004). This pathway plays important roles
in many aspects of Drosophila development, including embryonic
and eye development and larval hematopoiesis (reviewed in
(Arbouzova and Zeidler, 2006)). Sustained JAK/STAT signaling in
the ﬂy eye during development leads to an enlarged eye that is 2-3
times larger than wild type (Bach et al., 2003; Juni et al., 1996; Tsai
and Sun, 2004). Furthermore, loss of tumor suppressor genes tsg-101
and vps25 leads to excessive activation of JAK/STAT pathway
signaling and over-growth of the eye, and this phenotype is
suppressed by removal of one copy of Stat92E (Herz et al., 2006;
Moberg et al., 2005; Thompson et al., 2005; Vaccari and Bilder,
2005). In contrast, global loss of Stat92E during eye development
leads to an ablated eye and lethality prior to adulthood (Ekas et al.,
2006; Hou et al., 1996; Tsai et al., 2007; Yan et al., 1996).
Stat92E is a 761 amino acid protein that shares a similar domain
structure to other STATs and that is most similar to human STAT5with
37% identity (Hou et al., 1996; Yan et al., 1996; Zeidler et al., 2000).
Despite the sequence similarity between mammalian STATs and
Stat92E, the functional requirements of the different domains in
Stat92E are largely unknown, and an in-depth structural analysis of
this protein has not been undertaken. To address this issue, we
designed in vivo rescue assays and in vitro readouts to investigate the
role of the N- and C-terminal domains in Stat92E. We also examined
the requirement of Arg442, which is conserved in the majority of
mammalian STATs and is mutated to Pro in the strong hypomorphic
allele Stat92E85C9 (Silver and Montell, 2001; Wang and Levy, 2006a).
Surprisingly, we found that neither the ﬁrst 133 nor the last 36 amino
acids are required for Stat92E function. Furthermore, removal of both
of these domains simultaneously resulted in a constitutively active
form of Stat92E, the oncogenic activity of which depends on
phosphorylation of Y711. We also demonstrated that Arg442 is required
for Stat92E function, presumably because it forms a key STAT:DNA
contact point.
Materials and Methods
Genetics
These stocks are described in FlyBase: Stat92E85C9; Stat92E397;
Stat92E06346; Stat92Ej6C8; outstretched (os); UAS-upd; UAS-hop; tub-
Gal4; Df(3R)H-B79; UAS-GFP; ey-Gal4 (Hauck et al., 1999); P[AyGAL4]25 P[UAS-GFP.S65T]T2; hs-ﬂp MKRS/ TM6B; ey-Gal4, UAS-ﬂp (Stowers
and Schwarz, 1999); M(3)96C; Ribosomal protein S3 (RpS3)1; and
FRT82B ry506. We also used 10xSTAT-GFP (Bach et al., 2007). actin-
Gal425/CyO was a gift of Norbert Perrimon. Crosses were maintained
at 25 °C.
We used the Mosaic Analysis with a Repressible Cell Marker
(MARCM) technique to generate positively-marked Stat92E85C9 clones
that over-expressed Stat92EΔNΔC (Lee and Luo, 1999).
For the MARCM analyses, we crossed w; UAS-3HA-Stat92EΔNΔC/
UAS-3HA-Stat92EΔNΔC; FRT82B Stat92E/TM6C,Tb,Sb ﬂies to ey-ﬂp, UAS-
GFP; tub-Gal4/CyO; FRT82B tub-Gal80/TM6B,Tb or hs-ﬂp, UAS-GFP
6xMyc, tub-Gal4; +/+; FRT82B tub-Gal80/TM6B,Tb.
In animals possessing the ey-Gal4, UAS-ﬂp (EGUF) chromosome, the
ey promoter drives expression of the yeast Gal4 transactivator from the
earliest stages of eye development (Stowers and Schwarz, 1999). Gal4
stimulates the expression of genes under the control of Upstream
Activating Sequences (UAS) via the UAS/Gal4 technique (Brand and
Perrimon, 1993). In this case, Gal4 induces ﬂp, and FLP induces mitotic
recombinantion between homologous Flippase Recognition Target (FRT)
sites by means of the FLP/FRT technique (Xu and Rubin, 1993).Minutes
are mutations in ribosomal genes that cause slow growth when
heterozygous and lethality when homozygous, providing a growth
advantage to the homozygous (e.g., Stat92E) tissue (Lambertsson, 1998;
Morata and Ripoll, 1975). Minute clones were made using FRT82B M(3)
96C, arm-lacZ or FRT82B RpS31, ubi-GFP stocks. FRT82B ry506 was used as
the control+chromosome. When EGUF ﬂies also carry a UAS-3HA-
Stat92E transgene, ey-Gal4 drives expression of both UAS-ﬂp and UAS-
3HA-Stat92E in the eye disc. This results in the generation of
homozygous Stat92Emutant tissue and the expression of 3HA-Stat92E
proteins speciﬁcally in eye disc cells.
Clones mis-expressing hop and Stat92EΔNΔC were generated by
crossing UAS-hop or UAS-Stat92EΔNΔC ﬂies with P[AyGAL4]25 P[UAS-
GFP.S65T]T2; hs-ﬂpMKRS/ TM6B ﬂies, in which FLP is under the control
of the heat-shock promoter (Ito et al., 1997).
Transgene generation
Constructs
UASP-3HA-Stat92EFL (Ekas et al., 2006)
UASP-3HA-Stat92EΔN
UASP-3HA-Stat92EΔC
UASP-3HA-Stat92EΔNΔC
UAST-3HA-Stat92EΔNΔCY711F
UAST-3HA-Stat92EY711F
UASP-3HA-Stat92ER442P
UAST-3HA-Stat92ER442K
UASP-3HA-Stat92ER442A
Ac5c-hop-myc-his
socs1-luc
Primers
Stat92EΔN
5'DELTA1-133
5’ TTTTTGGATCCATGAACAACACGCCCATGGTTACCGGG 3’
3'DELTA1-133
5’ GTTGGTGGCGCCAGTTCTTGAGCTCG 3’
Stat92EΔC
5'delta725-761
5’ CAGATCCGTGTGTGGACCCTGTCCTTAC 3’
3'delta725-761
5’ TTTTGCGGCCGCTCCGTTTCTACAAACGTGAACATGCAATG 3’
Stat92EΔNΔCY711F
5’ Primer
5’ CTCGTCCTAGATCCTGTGACCGGTTTTGTGAAGAGCACATTG-
CATGTTCAC 3’
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5’ GTGAACATGCAATGTGCTCTTCACAAAACCGGTCACAGGATCTAG-
GACGAG 3’
Stat92EY711F
5’ B YF NEW
5' GTTCTAGATCCTGTGACCGGTTTTGTGAAGAGCACATTGCATGTT-
CAC 3'
3’ B YF NEW
5' GGGCTATGCGGCCGCAAAGTTCTCAAAGTTTGTAATCGTATC 3'
Stat92ER442P
5'R442PB
5’ GCCCTTCTTTTCTGCCGGCTTGATCTTCTTCAG 3’
3'R422PA
5’ CTGAAGAAGATCAAGCCGGCAGAAAAGAAGGGC 3’
Stat92ER442K
5'R442K B
5’ CTGAAGAAGATCAAGAAGGCAGAAAAGAAGGGC 3’
3'R442K A
5’ GCCCTTCTTTTCTGCCTTCTTGATCTTCTTCAG 3’
Stat92ER442A
5’ R442A B
5’ CTGAAGAAGATCAAGGCGGCAGAAAAGAAGGGC 3’
3’ R442A A
5’ GCCCTTCTTTTCTGCCGCCTTGATCTTCTTCAG 3’
Ac5c-hop-myc-his
5’ Oligo (Oligo 37)
5’ GAGTATCTGCAATCTGGTTCCTTCGAC 3’
3’ Oligo (Oligo 38) (to put an XbaI site at 3’ end of hop cDNA and
subclone in frame with Myc and His tags)
5’ GGAAATCTAGAAACTCGGCATCCGTCGGCTGATTCGGCGGCGAC 3’
socs1-luc
5’ Oligo
5’-TTTTTAGATCTGACTGTTTACCGCTTGCGGGTCGCATTTC-3’ (BglII
site)
3’ Oligo
5 ’-TTTTTGGATCCCCTTAACAACTGGCTTGAACTTATGTTTA-3 ’
(BamHI site).
Transgene generation
A full-length Stat92E cDNA containing three N-terminal HA tags
was ligated into UASP to generate the UASP-3HA-Stat92EFL transgene
as described in (Ekas et al., 2006). We have subsequently discovered
that the 3HA-Stat92EFL transgene has a point mutation which results
in an Ala substitution of Ser at position 8. Thismutation does not effect
the function of the 3HA-Stat92EFL protein since it can rescue Stat92E
loss-of-function phenotypes ((Ayala-Camargo et al., 2007; Ekas et al.,
2006), this study and data not shown). The constructs in this study
were engineered by polymerase chain reaction (PCR) using the
primers above and the C5HA3-3HA-Stat92EFL plasmid as a template.
C5HA3 is a pBluescript KS-based vector (Nybakken et al., 2005). The 5’
end of the C5HA3 polylinker includes an ATG immediately upstream of
sequence encoding three HA epitopes, followed by an in-frame BamHI
site. At the 3’ end, a NotI site immediately precedes and is in frame
with a stop codon. All Stat92E constructs in this study were designed
to have BamHI (5’) and NotI (3’) ends. After digestion with BamHI and
NotI, the insert was ligated into C5HA3 that had also been digested
with BamHI and NotI. For the 3HA-Stat92EΔN, 3HA-Stat92EΔC and 3HA-
Stat92ER442P plasmids, the insert was excised from C5HA3 by digestion
with BssHII. The 3’ recessed termini were ﬁlled in with Klenow and
were ligated into UASP (Rorth, 1996) that had been cut with BamHI,
ﬁlled in Klenow and treated with Shrimp Alkaline Phosphatase (SAP)
(Roche). For 3HA-Stat92EΔNΔC, a ∼400 bp fragment deleting the ﬁrst133 amino acids was generated by PCR using the primers for the 3HA-
Stat92EΔN construct. This fragment was digested with BamHI and ClaI
and ligated into the C5HA3-3HA-Stat92EΔC vector that had been
digested with BamHI and ClaI. It was subsequently cloned into UASP as
described above. For 3HA-Stat92EΔNΔCY711F, 3HA-Stat92ER442K, 3HA-
Stat92ER442A, and 3HA-Stat92EY711F, oligos containing an AvrII restric-
tion site weremade to the 5’ and 3’ ends of the Stat92E transgenes and
PCR was then used to remove the entire transgenic sequence
(including the 3 HA tags). Inserts were cut with AvrII and ligated
into UAST (Brand and Perrimon, 1993) that had been cut with XbaI
and treated with SAP. Throughout the text, these constructs are
frequently referred to without the “UAS” preface. Transgenic lines
were made by injection into w1118 Drosophila embryos (CBRC
Transgenic Fly Core, Charlestown, MA). Multiple insertions of each
UAS-3HA-Stat92E transgene were tested in each assay, and similar
results were obtained for each construct.
To make the Ac5c-hop-myc-his construct, we subcloned the entire
∼5 kb ApaI-XbaI fragment of the hop cDNA from Bluescript-hop (Binari
and Perrimon, 1994) into pcDNA3.1(-)/myc-His B (Invitrogen). The
resulting plasmid was called pcDNA3.1-hop-myc-His-ApaI-XbaI. The
parental pcDNA3.1(-)/myc-His B plasmid contains C-terminalMyc and
His epitope tags followed by a stop codon and preceded by unique
restriction enzyme sites. To remove the stop codon from the
pcDNA3.1-hop-myc-His-ApaI-XbaI plasmid, we ampliﬁed by PCR a
600 bp fragment of the C-terminal end of hop and mutated the stop
codon, inserted an XbaI site and engineered it to be in frame with the
Myc and His tags. This fragmentwas digestedwith PﬂMI (a unique site
in hop) and XbaI and the resulting 355 bp band was puriﬁed and
ligated into the pcDNA3.1-hop-myc-His-ApaI-XbaI plasmid vector at
the PﬂMI and XbaI sites. The resulting plasmid pcDNA3.1-hop-myc-his
was cut with NotI and PmeI, which removes 500 bp of the 5'UTR of the
hop cDNA but leaves the start site, and the epitope tags intact. The
NotI-PmeI fragment was treated with SAP and subcloned into the
Actin5c (Ac5c) plasmid that had been digested with NotI and HpaI and
treated with SAP. The construct was veriﬁed by sequencing and by
Western blotting (data not shown). In the text describing the in vitro
transfection assays, “Hop-Myc-His” is also referred to as “Hop”.
To generate the socs1-luc reporter we used PCR to amplify an 862 bp
fragment of genomic Socs36E intron 1 DNA from isogenized FRT42 ﬂies
(Janody et al., 2004) with BglII (5’) and BamHI (3’) ends. After digestion
with BglII and BamHI, the insert was ligated into a pGL3 Basic Vector
(Promega) at the BglII site. socs1-lucwas excised from pGL3 at SmaI and
XbaI sites and ligated in pCaSpeR 4 at SpeI and XbaI sites.
in situ hybridization and antibody staining
in situ hybridization and antibody stainings were performed as
described in (Bach et al., 2003; Flaherty et al., 2009). We used mouse
anti-Discs large (Dlg) (1:50) (Developmental Hybridoma Studies
Bank (DHSB)); rabbit anti-β-galactosidase (1:100) (Cappel); rat anti-
HA (1:1000) (clone 3F10, Roche); 4',6-diamidino-2-phenylindole
(DAPI) (1:1000) (Invitrogen); rabbit anti-Stat92E (1:1000) (Flaherty
et al., 2010) and ﬂuorescent secondary antibodies at 1:250 (Jackson
Laboratories). Fluorescent images were taken of eye discs (at 25x)
using a Zeiss LSM 510 confocal microscope and of cells (at 40x) using a
Nikon Eclipse TE2000-E microscope and digital camera. Bright ﬁeld
pictures were taken at 5x using a Leica MZ 8 microscope with an
Optronics digital camera or at 20x using a Zeiss Axioplan microscope
with a Nikon Digital Sight DL-UL camera.
Western blot analysis
Extracts from S2 cells were prepared by lysis in a buffer containing
1xPBS, 150 mM NaCl, 1% Triton, 1x Complete protease inhibitors
(Roche), 2 mM sodium orthovanadate, and 0.5 mM EDTA. Immuno-
precipitation was performed as described in (Bach et al., 1996) using
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(Amersham Biosciences). Immunoprecipitated proteins were eluded,
subjected to SDS-PAGE and immunoblotted using standard methods.
We used PY-20 (1:1000) (BD Biosciences); mouse anti-HA (1:1000)
(Covance); and rabbit anti-Stat92E (1:1000) (Flaherty et al., 2010).
Horseradish peroxidase secondary antibodies (Jackson ImmunoRe-
search) were used at 1:10000. The blots were developed using
Amersham ECL Western Blotting Analysis System (GE Healthcare).
Luciferase assay
Luciferase assays were performed as described in (DasGupta et al.,
2005). 6x104 S2 cells were seeded in 96-well plates and transfected
using Effectene (Qiagen)with 40 ng of Ac5c-Gal4 (Zeidler et al., 2004),
40 ng of UAS-3HA-Stat92E transgene, 40 ng of socs1-luc, 40 ng of
Renilla-luciferase and 4 ng of Ac5c-hop-myc-his. Ac5c was added as
needed to maintain a constant concentration of DNA. After 48 hours,
ﬁreﬂy luciferase (from socs1-luc) and Renilla luciferase activity were
monitored in cell lysates using Dual-Glo Luciferase Assay System
(Promega) and a Perkin Elmer Wallac EnVision 2103 multilabel plate
reader. Experiments were performed four times in quadruplicate. For
each data point, ﬁreﬂy luciferase values were divided by appropriate
Renilla luciferase value. Relative luciferase units were then calculated
by Nexperimental/ Nconstant where Nexperimental is the value of
ﬁreﬂy luciferase/ Renilla luciferase and Nconstant is Ac-Gal4 ﬁreﬂy
luciferase/ Renilla Luciferase.
Stat92E homology model
The homology model was built as described in (Cardozo et al.,
1995) using the ICM-Pro software program (Molsoft, LLC, La Jolla, CA).
Brieﬂy, the crystal structure of phosphorylated STAT1 was used as a
template (pdb code 1bf5) for the sequence of Stat92E (Q24151). The
similarity between the sequence of the template and the sequence of
Stat92E is high enough to virtually guarantee that Stat92E adopts the
same overall 3D fold as the template. After threading the Stat92E
sequence onto the STAT1 crystal structure using the alignment
between the two sequences as a guide, side-chains and loops were
energy minimized to obtain the ﬁnal 3D structural model.
Alignments
Protein sequences were obtained from NCBI. The DNA binding
domains were aligned by the Clustal-W method using DS Gene 1.5
software. Optimal STAT binding elements used in this study were
originally reported in (Decker et al., 1997;Wang and Levy, 2006b; Yan
et al., 1996).
Results
Generation of UAS-3HA-Stat92E transgenes
We previously reported the generation of a full length Stat92E
transgene UAS-3HA-Stat92EFL, which encodes the 761 amino acid
Stat92E protein tagged at the N-terminus by 3 tandem HA epitopes
(Ekas et al., 2006). This transgene fully rescues Stat92E phenotypes in
the developing Drosophila eye (Fig. 3D and (Ekas et al., 2006)). To
determine the functionally important sequences in Stat92E, we made
deletions and substitutions to the 3HA-Stat92EFL construct and then
assessed their performance in several assays (Fig. 1B).
Stat92E allelic series
First, we determined the Stat92Emutant background in which the in
vivo experiments should be performed. We used lethal-phase analysis to
assess the strongest Stat92E loss-of-function allele. Stat92E85C9 andStat92E397 are ethyl methanesulfonate-induced alleles that are caused
bya substitution ofArg at position442 to a Pro andof a Trp to a stop codon
at position 594, respectively (Silver andMontell, 2001). Both Stat92E06346
and Stat92Ej6C8 have P-element insertions 5’ to the start site of the Stat92E
gene,whichpresumably lower transcription of this gene (Houet al., 1996;
Spradling et al., 1999). While P-element mutations are typically
hypomorhpic, Stat92E06346 has been reported to be a null (Henriksen
et al., 2002; Hou et al., 1996; Mukherjee et al., 2005; Zeidler et al., 1999).
However, the level of Stat92EmRNA or protein in this mutant has never
been published. We monitored the zygotic lethal phase of these Stat92E
alleles placed in trans to a chromosomal deﬁciency Df(3R)H-B79 that
removes the Stat92Egene. 30%of Stat92E85C9/Df , 30%of Stat92E397/Df,22%
of Stat92E06346/Df and 24% of Stat92Ej6C8/Df animals died during
embryogenesis. In all four crosses, the embryos that did hatch
subsequently died in the ﬁrst larval instar (Fig. 2A). These data indicate
that 85C9 and 397 are stronger alleles than 06346 and j6C8. In support of
this conclusion, we found that Stat92E85C9 or Stat92E397 clones in the eye-
antennal, wing or leg disc generated stronger phenotypes than
Stat92E06346 or Stat92E j6C8 clones ((Ayala-Camargo et al., 2007; Ekas
et al., 2006) and data not shown). We propose this Stat92E allelic series,
starting with the strongest: 85C9=397N j6C8N06346.
Characterization of Stat92E85C9 and Stat92E397
To further characterize the 85C9 and 397 alleles, we established
assays in the developing eye-antennal disc, which is derived from a
primordium of ∼50 progenitor cells and gives rise to the adult eye,
antenna and head capsule (Dominguez and Casares, 2005). In
wildtype eye discs, activation of the JAK/STAT pathway promotes
proliferation of these progenitor cells and formation of the eye ﬁeld
(Bach et al., 2003; Chao et al., 2004; Ekas et al., 2006; Reynolds-
Kenneally and Mlodzik, 2005; Tsai and Sun, 2004). An eye-antennal
disc composed of almost entirely homozygous Stat92E mutant tissue
(hereafter referred to as Stat92E M+) was generated using ey-Gal4,
UAS-ﬂippase (ﬂp) (EGUF) and Minute techniques (see Materials and
Methods). Stat92E mRNA was ubiquitously expressed in an eye disc
from animals carrying a control wild type chromosome in an EGUF
Minute background (referred to as+M+) (Fig. 2B). It was also
ubiquitously expressed in eye discs in EGUF Stat92E85C9 M+ or
Stat92E397 M+ animals (Figs. 2C, D). These data indicate that 85C9
and 397 alleles are not RNA nulls. To determine whether 85C9 is a
protein null, we stained Stat92E M+ eye discs with an antibody that
recognizes the last 15 amino acids of Stat92E, a region lacking in
Stat92E397 (Chen et al., 2002; Flaherty et al., 2010; Silver and Montell,
2001). As expected, in Stat92E397 M+ eye discs, the Stat92E antibody
staining speciﬁcally overlapped with heterozygous tissue, which have
one wild type copy of Stat92E (Fig. 2F, F', arrow). In contrast,
Stat92E85C9 M+ eye discs exhibited ubiquitous Stat92E staining in
homozygous mutant tissue and reduced expression in GFP-positive
heterozygous tissue (Fig. 2E, E', arrow), demonstrating that this allele
is not a protein null.
in vivo function of Stat92E variants
Themajority of animals harboring Stat92E85C9M+ or Stat92E397M+
clones generated by EGUF do not hatch from the pupal case and those
that do eclose exhibit small or ablated eyes (Figs. 3B, C and (Ekas et al.,
2006)). We designed a rescue assay that would generate eye disc cells
which were homozygous mutant for Stat92E and also mis-expressed a
recombinant 3HA-Stat92E protein (seeMaterials andMethods). Using
this assay, we found that the phenotypes and hatching rate in EGUF
Stat92E85C9 M+ or Stat92E397 M+ animals were completely rescued by
the expression of UAS-3HA-Stat92EFL but not by an irrelevant UAS-
linked gene (Fig. 3D,E and (Ekas et al., 2006)). Mis-expression of
Stat92EΔN, which lacks the ﬁrst 133 amino acids, Stat92EΔC, which
lacks the last 36 amino acids (residues 726-761), or Stat92EΔNΔC,
Fig. 2. Stat92E85C9 and Stat92E397 are strong hypomorphic alleles. (A) Lethal phase analysis of Stat92E85C9, Stat92E397, Stat92E06346, Stat92Ej6C8 alleles in trans to the Df(3R)H-B79
deﬁciency that removes the Stat92E gene. Both 85C9/Df and 397/Df result in 30% embryonic lethality, while 06346/Df and j6C8/Df result in 22% and 24%, respectively. (B-F) Large
Stat92E clones were generated using ey-Gal4, UAS-FLP (EGUF) in a Minute (M+) background. (B–D) Stat92E mRNA is produced in both Stat92E85C9 and Stat92E397 mutant
backgrounds. Second instar eye discs in a control EGUF+M+ (B), an EGUF Stat92E85C9 M+ (C), or an EGUF Stat92E397 M+ background (D). (E,F) Stat92E antibody staining in EGUF
Stat92E85C9 M+ (E) or EGUF Stat92E397M+ (F) eye discs. Stat92E homozygousmutant tissue is marked by the absence of GFP (green), Stat92E is red and Dlg, whichmarks cell outlines,
is blue. The Stat92E antibody detects Stat92E protein in Stat92E85C9 M+ tissue (E). However, this antibody does not recognize antigen in Stat92E397 M+ tissue because Stat92E397 lacks
the region to which the antibody binds (last 15 amino acids of Stat92E) (F). An arrow marks GFP+ Stat92E-/+ heterozygous tissue in E,F. For all ﬁgures, eye discs and adult eyes are
oriented anterior to the left and dorsal to the top.
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Fig. 3. Stat92E phenotypes are rescued by Stat92EΔN, Stat92EΔC and Stat92EΔNΔC but not by Stat92EY711F or the Stat92ER442 mutants. Large patches of Stat92E mutant tissue were
generated using an EGUF chromosome and the Minute technique, where ey-GAL4 drives UAS-ﬂp, which then stimulates mitotic recombination, as well as expression of UAS-3HA-
Stat92E rescue transgenes. (A) A+M+ adult control eye is the same size as wild type. (B,C) Stat92E85C9 M+ adults exhibit a no-eye (B) or small-eye (C) phenotype. (D-L) A Stat92EFL
transgene rescues the Stat92E85C9 phenotype (D), as do Stat92EΔN (G), Stat92EΔC (H), and Stat92EΔNΔC (I). In contrast, UAS-GFP (E), Stat92EY711F (F), Stat92ER442P (J), Stat92ER442K (K),
and Stat92ER442A (L) do not. (M-R) Stat92E transgenes behave similarly when tested in EGUF Stat92E397 M+ eye discs. (S) Lethal phase analysis of Stat92E variants. Stat92E transgenes
were expressed using tub-Gal4 in 85C9/85C9 zygotic mutants that still have maternal Stat92E mRNAs and the genotype w; tub-Gal4/UAS-3HA-Stat92E; 85C9/85C9. The FL, ΔN, ΔC,
and ΔNΔC transgenes signiﬁcantly delayed the 85C9/85C9 lethal phase to late pupal or infrequently adult stages. In contrast, the Y711F, R442P, R442K and R442A transgenes do not.
Rather they increased the embryonic lethality in 85C9/85C9 animals. First (L1), second (L2), and third (L3) larval instar, early (EP) and late (LP) pupal stage. Animals counted: 85C9/
Df=129; 85C9/85C9=100; FL=91; ΔN=107; ΔC=103; ΔNΔC=101; Y711F=194; R442P=157; R442K=160; R442A=111.
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restored the size of the Stat92E85C9 M+ eye to wild type (Fig. 3G-I). In
addition, all of the pupae in these crosses hatched from their pupal
cases. By contrast, mis-expression of Stat92EY711F did not increase the
size of the Stat92E M+ small eye, conﬁrming that Tyr711 is critical for
Stat92E function in vivo as it is in vitro (Fig. 3F and (Yan et al., 1996)).We quantiﬁed the eye area of 20 females of each genotype, which
conﬁrms these qualitative results (Fig. S1). Importantly, all UAS-3HA-
Stat92E variants gave identical results in the Stat92E397 background,
indicating that Stat92E85C9 phenotypes are not due to an additional
lethal mutation on the 85C9 chromosome (Fig. 3M-R and data not
shown). All transgenes were expressed in the eye disc, although Y711F
628 L.A. Ekas et al. / Developmental Biology 344 (2010) 621–636(and non-functional R442 mutants, see below) had lower expression in
Stat92E M+ mutant tissue (Fig. S2). The reduced expression of HA in
these discs might result from aberrations in eye ﬁeld patterning and/
or to ectopic expression of signaling molecules like the Wnt family
memberWingless, which represses JAK/STAT signaling, and the Notch
pathway ligand Serrate (Ayala-Camargo et al., 2007; Ekas et al., 2006;
Flaherty et al., 2009; Tsai et al., 2007). Nevertheless, these data
demonstrate that Tyr711, but not the N-terminal 133 or the C-terminal
36 amino acids, are required for Stat92E function in vivo.
To conﬁrm that the in vivo functionality of these variants is not
speciﬁc to eye development, we tested the ability of the Stat92E
variants to delay the Stat92E85C9 lethal phase. We used the UAS/Gal4
technique to mis-express UAS-Stat92E transgenes in a homozygous
Stat92E85C9 background using tubulin-Gal4 (tub-Gal4), which is
ubiquitously expressed during all developmental stages (Brand and
Perrimon, 1993). It should be noted that these animals still have
maternal Stat92EmRNAs. 30% of 85C9/85C9 homozygotes died during
embryonic stages, the same value as 85C9/Df (Figs. 2A and 3S). Mis-
expression of Stat92EFL signiﬁcantly delayed this lethal phase and the
majority of animals died during pupal stages (Fig. 3S). Mis-expression
of Stat92EΔN, Stat92EΔC or Stat92EΔNΔC also delayed the lethal phase
in a manner similar to Stat92EFL (Fig. 3S). It is unclear why these
transgenes did not rescue Stat92E85C9 homozygotes to adulthood
because the pupae from these crosses appeared normal upon
dissection (data not shown). Another constitutive driver (actin-
Gal4) shifted the 85C9/85C9 lethal phase to late larval stages when
mis-expressing Stat92EFL (data not shown). These data suggest that
these drivers are not strong enough during larval/pupal stages or do
not target one or more critical tissues at sufﬁcient levels to insure
survival to adult stages. Stat92EY711F could not delay the lethal phase
of Stat92E85C9 homozygous animals. Moreover, it had dominant
negative effects as more than 95% of these animals died during
embryonic stages (Fig. 3S). Importantly, all UAS-3HA-Stat92E variants
gave identical results in Stat92E397 zygotic homozygotes (data not
shown). These data suggest that the N- and C-terminal domains are
not required for Stat92E function during all stages of Drosophila
development, while Tyr711 is essential.in vitro function of Stat92E variants
To investigate whether the 3HA-Stat92E variants can activate gene
transcription in vitro, we generated a transcriptional reporter socs1-luc
by placing an 862 bp fragment from intron 1 of the Socs36E gene
containing four putative Stat92E binding sites upstream of luciferase
(Bach et al., 2007; Baeg et al., 2005; Karsten et al., 2002).We transfected
S2 cells with Ac5c-hop-myc-his that drives constitutive expression of
Hop-Myc-His, with Ac5c-Gal4 that induces UAS transgenes in vitro
(Klueg et al., 2002), and with UAS-3HA-Stat92EFL. We used 4 ng of Ac5c-
hop-myc-his, which activated the reporter only slightly above the Ac5c-
Gal4 control (Fig. 4A, Lanes 1,2). Expression of Stat92EFL alone did not
activate the reporter above Hop-Myc-His control (Fig. 4A, Lane 3). By
contrast, Stat92EFL expressed together with Hop-Myc-His resulted in a
signiﬁcant increase in luciferase activity (Fig. 4A, Lane 4).Fig. 4. Transcriptional activation by and expression of Stat92E variants. (A,B) S2 cells transie
(A) Ac5c-Gal4 alone, Ac5c-hop-myc-his alone and Stat92EFL alone do not signiﬁcantly activa
activate the reporter over baseline levels. In contrast, Stat92EY711F, Stat92ER442P, Stat92ER442
luc, suggesting that it is a dominant-active mutation (lane 7). (C) The constitutive acti
(Stat92EΔNΔCY711F, abbreviated Stat92ENCYF) abolishes Stat92EΔNΔC activity either in the pres
expression and activation of Stat92E variants in S2 cells which were transiently transfected a
not tyrosine phosphorylated (lane 1). In contrast, all Stat92E variants are phosphorylated i
Stat92E speciﬁc or HA speciﬁc antibodies reveals that all Stat92E variants are expressed at
detected by the Stat92E antibody because they lack the antigen recognized by this antib
pervanadate (lanes 2-10). Activation of Stat92EFL by pervanadate (lane 1) serves as a positWe assessed which residues of Stat92E were required for the
activation of socs1-luc. Stat92EΔN and Stat92EΔC robustly activated the
reporter to levels observedwith Stat92EFL and onlywhen expressedwith
Hop-Myc-His (Fig. 4A, B, Lanes 5, 6). In contrast, Stat92EY711F could not
activate the reporter socs1-lucwhen expressed alone or with Hop-Myc-
His (Fig. 4A, B, Lanes 8). Western blotting demonstrated that all Stat92E
constructs were expressed at similar levels and at the predicted Mr
(Fig. 4D). We further showed that all constructs were tyrosine
phosphorylated after treatment of the cells with pervanadate, which
activates Stat92E in a ligand-independentmanner (Sweitzer et al., 1995),
but not in untreated cells (Fig. 4D, E). Stat92E contains thirteen tyrosine
residues, including Y711, and presumably it is these other tyrosine
residues that are phosphorylated after treatmentwith pervanadate (Hou
et al., 1996; Yan et al., 1996).Stat92EΔNΔC is a constitutive transcriptional co-activator and has
dominant-active behavior in vivo
Strikingly, in the presence of Hop-Myc-His, Stat92E lacking both the
N and C termini (Stat92EΔNΔC) induced luciferase activity signiﬁcantly
more robustly than Stat92EFL or than the single N- and C-terminal
truncations, demonstrating that it has increased transcriptional activa-
tion capabilities (Fig. 4A, Lane 7). Furthermore, Stat92EΔNΔC alone
induced high levels of socs1-luc in the absence of Hop-Myc-His (Fig. 4B,
Lane 7). These data strongly suggest that the Stat92EΔNΔC protein is
constitutively active. Importantly, ectopic expression of Stat92EΔNΔC
with ey-Gal4 resulted in moderate overgrowth of eye tissue (Fig. 5C).
Despite the low penetrance of this phenotype (∼5%), the Stat92EΔNΔC-
induced overgrowth is signiﬁcant because this gain-of-function pheno-
type is never observed with ectopic expression of other Stat92E
transgenes (Figs. 5A,B and S1).
To determine whether Stat92EΔNΔC exhibits constitutive activity in
other tissues, we examined its ability to induce melanotic tumors.
Ectopic expression of UAS-hop in ﬂip-out clones resulted in ligand-
independent, autonomous activation of Stat92E and gave rise to
melanotic tumors (Fig. 5D and (Ekas et al., 2006)). Similarly, ectopic
expression of Stat92EΔNΔC in ﬂip-out clones also caused tumors
(Fig. 5E). Melanotic tumors were never seen in clones mis-expressing
Stat92EFL (data not shown). Ectopic expression of Stat92EΔNΔC or Hop
also induced cell-autonomous expression of an in vivo Stat92E
transcriptional reporter (Fig. 5H, data not shown and (Bach et al.,
2007)). By contrast, mis-expression of Stat92EFL did not activate this
reporter (data not shown).We tested constitutive nuclear localization
or constitutive tyrosine phosphorylation as possible mechanisms for
the dominant active behavior of Stat92EΔNΔC. Stat92EΔNΔC is cyto-
plasmic in S2 cells in the absence of stimulation and translocates to
the nucleus after activation, ruling out the former model (Fig. 5F, G).
Stat92EΔNΔC was not tyrosine phosphorylated in untreated cells
(Fig. 4E, Lane 5) but became tyrosine phosphorylated in response to
pervanadate (Fig. 4D, Lane 5). These data suggest that the latter model
is also not correct. However, Stat92EΔNΔC could contain levels of
phosphotyrosine higher than endogenous Stat92E but below the level
of detection of the PY-20 antibody used in this experiment.ntly transfected with the socs1-luc reporter, Ac5c-Gal4, and Ac5c-hop-myc-his as noted.
te socs1-luc. In the presence of Hop, Stat92EFL, Stat92EΔN, Stat92EΔC, and Stat92EΔNΔC
K, and Stat92ER442A do not. (B) In the absence of Hop, only Stat92EΔNΔC activates socs1-
vity of Stat92EΔNΔC depends on phosphorylation of Y711. Mutation of Tyr711 to Phe
ence or absence of Hop (lanes 7 and 8). (D,E) Western blot analysis conﬁrms predicted
nd stimulated as indicated. (D) In the absence of pervanadate, Stat92EFL is expressed but
n response to pervanadate treatment (lanes 2-10). Reprobing the blot with C-terminal
their predicted Mr. Stat92EΔC, Stat92EΔNΔC and Stat92ENCYF (lanes 4,5 and 10) are not
ody. (E) None of the Stat92E variants are tyrosine phosphorylated in the absence of
ive control for tyrosine phosphorylation.
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630 L.A. Ekas et al. / Developmental Biology 344 (2010) 621–636We determined that Stat92EΔNΔC acts epistatically to upd because
its mis-expression speciﬁcally in the eye rescued the small-eye
phenotype of outstretched (os), a viable upd allele that has small eyes
and outstretchedwings (Lindsley and Zimm, 1992). upd is an X-linked
gene, and os/Y males or os/os females manifest these eye and wing
phenotypes. We used ey-Gal4 (Hauck et al., 1999) to drive expression
of Stat92EΔNΔC in os/Ymales and compared the size of the eye in os/Y;
Stat92EΔNΔC/CyO and os/Y; Stat92EΔNΔC/ey-Gal4 males (n=80 eyes
for both genotypes). We found that os/Y; Stat92EΔNΔC/CyO ﬂies had
adult eyes that were identical in size to os/Ymales, indicating that the
presence of the transgene alone does not generate a phenotype
(Fig. 5I and data not shown). In contrast, os/Y; Stat92EΔNΔC/ey-Gal4
males had eyes that were nearly identical to those in wild type +/Y
males and were signiﬁcantly larger than those in os/Y; Stat92EΔNΔC/
CyO males, an observation that is statistically signiﬁcant (pb10-34,
Student's T-test) (Fig. 5J, K). Notably, eyNStat92EΔNΔC did not rescue
the outstretched wing phenotype of os/Y ﬂies.
The dominant-active properties of Stat92EΔNΔC require Y711
Tyrosine phosphorylation on conserved C-terminal tyrosine
residues is required for the function of mammalian STATs and for
the constitutive activity of Cys mutants STAT3-C and STAT1-C (Li and
Shaw, 2006; Liddle et al., 2006). To examine whether this was also the
case for Stat92EΔNΔC, we generated a Stat92EΔNΔC transgene that has a
Tyr711 to Phe substitution (Stat92EΔNΔCY711F). We found that either in
the presence or in the absence of Hop, Stat92EΔNΔCY711F could not
activate socs1-luc above background levels (Fig. 4C, Lanes 7,8). This is
similar to the transcriptional co-activation abilities of a Stat92E that
only contains a substitution of Tyr711 to Phe (Figs. 4A, B, Lanes 8).
Therefore, the dominant-active abilities of Stat92EΔNΔC require
phosphorylation of Tyr711 and by inference the formation of a
phosphorylated, activated dimer.
Stat92EΔNΔC forms dimers with endogenous Stat92E following activation
To address whether the dominant-active behavior of Stat92EΔNΔC
resulted from dimer formation with a functional Stat92E, we
determined whether of Stat92EΔNΔC caused melanotic tumors in the
absence of endogenous Stat92E. We generated positively-marked
Stat92E85C9 clones that over-expressed Stat92EΔNΔC (see Materials
and Methods). We were unable to ﬁnd any melanotic tumors despite
the examination of hundreds of larvae harboring these clones (data
not shown). These data indicate that Stat92EΔNΔC causes tumors and
overgrowths only in tissues that contain a functional Stat92E protein.
This conclusion is supported by the observations that Stat92EΔNΔC
never caused over-growths in Stat92E85C9 M+ or Stat92E397 M+
mutant eye discs.
To address if there is a physical interaction between endogenous
Stat92E and Stat92EΔNΔC, we performed co-immunoprecipitation
experiments in S2 cells. We found that in the absence of pervandate
stimulation, endogenous Stat92E did not co-immunoprecipitate withFig. 5. Stat92EΔNΔC exhibits constitutive activity. (A-C) Dorsal view of adult heads from an
Stat92EFL (B) or of UAS-Stat92EΔNΔC (C) during larval eye development. Arrow (white) deno
standard was used to demonstrate that ectopic expression of Stat92EΔNΔC (C) but not Stat92
expressing Hop (Act≫hop) (D) or Stat92EΔNΔC (Act≫Stat92EΔNΔC) (E) have melanotic tum
not constitutively localized to the nucleus. S2 cells expressing Stat92EΔNΔC were unstimula
stimulation, Stat92EΔNΔC is cytoplasmic (F), but moves into the nucleus upon activation (G).
and the 10xSTAT-GFP reporter. Clones (anti-β GAL (red)), 10xSTAT-GFP (green), anti-Stat9
transcriptional reporter 10xSTAT-GFP in a cell-autonomous manner (red arrows). (I-J) Stat9
This phenotype was rescued in os/Y; UAS-Stat92EΔNΔC/ ey-Gal4 ﬂies, where Stat92EΔNΔC is s
3HA-Stat92EΔNΔC/CyO (red bar), os/Y; UAS-3HAStat92EΔNΔC/ CyO (green bar) or wild type
difference between the values of the red and green values is statistically signiﬁcant (pb10–34
cells were transiently transfected with the indicated plasmids and were unstimulated or tr
antibody andWestern blotted ﬁrst with Stat92E-C and subsequently HA antibodies. Endogen
(lane 1) and 3HA-Stat92EΔNΔC 67 kDa (lane 3). Endogenous Stat92E does not coimmunoprec
activation of the pathway, endogenous Stat92E present in anti-HA precipitates (lanes 2 andeither Stat92EFL or Stat92EΔNΔC (Fig. 5L, Lanes 1,3,5,7). In contrast,
after pervandate stimulation, endogenous Stat92E was detected in
immuno-precipitates of both Stat92EFL and Stat92EΔNΔC (Fig. 5L, Lanes
2,4,6,8). Taken together, these data indicate that endogenous Stat92E:
Stat92EΔNΔC dimers are required for dominant-active behavior of
Stat92EΔNΔC.
Arg442 is required for Stat92E-induced transcriptional activation
The Stat92E85C9 allele results from a substitution of Pro for Arg at
residue 442 (Fig. 1B) (Silver and Montell, 2001). This Arg residue is
conserved in the C. elegans STAT, STA-1, and in mammalian STATs 2, 3,
5, and 6 (Fig. 7C and (Wang and Levy, 2006b; Yan et al., 1996)). To
determine the functional importance of Arg at position 442 in Stat92E,
we generated these constructs: Stat92ER442P, which mimics the 85C9
mutation; Stat92ER442K, which contains a conservative substitution of
Arg442 to Lys; and Stat92ER442A, which contains a non-conservative
substitution of Arg442 to Ala.We found that Stat92ER442P cannot rescue
the Stat92E small-eye phenotype, shift the 85C9 lethal phase or
activate transcription (Figs. 3J, R and 4A, B, Lanes 9), which is
consistent with Stat92E85C9 being a strong hypomorph. We reasoned
that if a positive charge were required at position 442, then
Stat92ER442K should be functional, while Stat92ER442A should not.
However, we found that neither of these Stat92E variants could rescue
the Stat92E small-eye phenotype, shift the lethal phase or induce
socs1-luc transcription (Figs. 3K,L and 4A, B, Lanes 10 and 11).
Moreover, all of three Arg mutants had dominant-negative effects in a
Stat92E hypomorphic background. The embryonic lethality of 85C9
zygotic homozygotes rose to more than 70% with the expression of
these constructs, and the R442P, R442K and R442A (as well as the Y711F)
crosses had to be set up for one year to collect 20 adult females for
quantiﬁcation of area of the eye (Fig. 3S and Fig. S1). We ruled out the
possibility that the inactivity of the R442mutants was due to aberrant
expression (Figs. 4D, E, Lanes 7-9 and S2H-J). We also ruled out the
possibility that R442 was required for nuclear translocation. Sta-
t92ER442P was cytosolic in the absence of stimulation and translocated
to the nucleus upon treatment with pervanadate, similar to endoge-
nous Stat92E and Stat92EFL (Fig. 6A-D, G, H). By contrast, Stat92EY711F
remained cytoplasmic in both the presence and absence of stimula-
tion, as has been observed for mammalian STATs harboring Tyr to Phe
substitutions (Figs. 6E, F and (Levy and Darnell, 2002)). Lastly, the
R442 mutant proteins behaved like Stat92EFL with regards to tyrosine
phosphorylation: they contained undetectable levels of phospho-
tyrosine in the absence of stimulation and high levels following
pervanadate treatment (Fig. 4D, E, Lanes 7-9).We conclude that Arg442
is not required for Stat92E activation or for nuclear translocation but
that it is indispensible for transcriptional co-activation by Stat92E.
Arg442 may directly contact the minor groove of the DNA helix
We reasoned that Arg442 may be important for maintaining a
STAT-DNA interface. To test this hypothesis by observing whereimals in which ey-Gal4 (Hauck et al., 1999) drives expression of UAS-GFP (A), of UAS-
tes the distance from the medial posterior to the anterior lateral edge of the eye. This
EFL (B) leads to eye overgrowth. (D,E) Third instar larvae with randomly induced clones
ors (large tumors, red arrows; small tumors, black arrows in D,E). (F,G) Stat92EΔNΔC is
ted (F) or stimulated with pervanadate (G). HA (green), DAPI (blue). In the absence of
(H) A third instar eye disc harboring Stat92EΔNΔC-expressing-clones (Act≫Stat92EΔNΔC)
2E-C (blue). Ectopic expression of Stat92EΔNΔC induces the expression of the Stat92E
2EΔNΔC acts downstream of upd. An os/Y; UAS-Stat92EΔNΔC/CyOmale has small eyes (I).
peciﬁcally expressed in the eye disc (J). (K) Quantiﬁcation of the eye area in os/Y; UAS-
OreR +/Y males (blue bar). n=80 in each os/Y genotype. n=20 in wild type. The
, Student's T test). (L) Stat92EFL and Stat92EΔNΔC dimerize with endogenous Stat92E. S2
eated with pervanadate. 3HA-Stat92E proteins were immunoprecicipated with an HA
ous Stat92E has a predicted Mr of 85 kDa (lanes 2,4), the 3HA-Stat92EFL protein 90 kDa
ipitate with either variant in the absence of pervanadate (lanes 1 and 3). However, after
4).
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we generated a homology model of Stat92E based on the crystallo-
graphic structure of a phosphorylated STAT1 dimer bound to DNA
(Chen et al., 1998). This model revealed that Arg442 likely contacts
DNA directly, presumably by accessing the minor groove of the DNA
helix (Fig. 7B). The model comfortably positions the Arg442 side chainwith 484 A2 surface area of contact with the DNA bases in the minor
groove. Contact with the major groove or with other Stat92E binding
partners is unlikely from this location as long as DNA is bound to
Stat92E, since the loop on which Arg442 sits is nestled deeply in the
minor groove and should not extend out of the minor groove even if
it takes on a different conformation than that seen in the model.
Fig. 6. Stat92ER442P can translocate to the nucleus after activation. Untransfected S2 cells (A,B), or S2 cells transiently transfected with Stat92EFL (C,D), Stat92EY711F (E,F), or
Stat92ER442P (G,H). Cells were unstimulated (A,C,E,G) or stimulated with pervanadate (B,D,F,H). Stat92E (red), HA (green), and DAPI (blue). In the absence of stimulation,
endogenous Stat92E (A), Stat92EFL (C), Stat92EY711F (E), and Stat92ER442P (G) are cytoplasmic. Upon stimulation, endogenous Stat92E (B), Stat92EFL (D) and Stat92ER442P (H)
translocate to the nucleus. Stat92EY711F (F) does not translocate to the nucleus upon stimulation.
632 L.A. Ekas et al. / Developmental Biology 344 (2010) 621–636Interestingly, the location of Arg442 and the observation that Lys is not
functional at this position in Stat92E suggest that only protein side
chain:DNA interactions, which depend exclusively on the Arg
guanidinium group, are operative here for Stat92E. The list of
canonical candidate interactions of this type has been previously
published (Luscombe et al., 2001), and only one is possible with the
sequence of bases recognized by Stat92E, namely a complex, stacked
base minor groove interaction with a cytosine and thymine. This
complex would be lost with the Stat92ER422 mutation to Pro, which
eliminates the side-chain guanidinium group. Thus, our model and
the observed data suggests that Arg442 interacts with the T and C of
the TTCnnnGAA that is present in the optimal binding sites of nearly
all STAT proteins, including Stat92E and STA-1 (Fig. 7D and (Decker et
al., 1997)). These data suggest that Arg442 contributes to Stat92E's
ability to recognize its target DNA binding site.Discussion
In this study we use in vivo and in vitro assays to perform a
structure-function analysis of Stat92E. We ﬁnd that neither the N-
terminus (residues 1-133) nor the C-terminus (residues 725-761) is
required for Stat92E function in vivo and in vitro. However, when both
N- and C-termini are removed, the resulting protein Stat92EΔNΔC has
dominant-active properties, including oncogenesis. Furthermore, we
demonstrate that Stat92EΔNΔC with a Tyr to Phe substitution at
residue 711 (Stat92EΔNΔCY711F) is non-functional. We also showed
that both Stat92EY711F and Stat92ER442P are non-functional and
manifest dominant-negative activities in vivo. The lack of function of
the Stat92EY711F variant is likely due to an inability to form an
activated dimer, as has been previously reported (Yan et al., 1996).
Our data suggest that Stat92ER442P cannot function because it does notmaintain normal interactions between activated Stat92E dimers and
cognate DNA.
Our study is important for several reasons, perhaps foremost of
which is that we are the ﬁrst group to identify a dominant-active
Stat92E. The simultaneous removal of the N-terminal 133 and the C-
terminal 36 amino acids results in a truncated protein that has
constitutive activity, which causes melanotic tumors when mis-
expressed in wild type larvae and transactivates a Stat92E reporter
gene in vitro and in vivo in the absence of stimulation. We show that
the activity of Stat92EΔNΔC is dependent on the presence of Y711, as is
that of Stat92EFL. These data suggest that Stat92EΔNΔC is activated in a
manner similar to full length Stat92E (i.e., by reciprocal interactions
between SH2 domains and phosphorylated Y711 residues on adjacent
Stat92E proteins). Consistent with this, we show that Stat92EΔNΔC
forms a dimer with endogenous Stat92E (i.e., a Stat92E: Stat92EΔNΔC
dimer) after pervanadate stimulation. Therefore, Stat92EΔNΔC appears
to behave like wild type Stat92E that has lost a negative regulatory
component. One possibility is that removal of the N- and C-termini
prolongs the interaction between the Stat92E:Stat92EΔNΔC dimer and
DNA, leading to increased gene activation. Another is that Stat92E:
Stat92EΔNΔC dimers cannot be efﬁciently dephosphorylated and/or
return to an inactive dimer conformation, which may be required for
normal export of Stat92E dimers to the cytoplasm (Chen et al., 2003).
Constitutive activity is not observed by the removal of either the N or
C-terminus domain individually, and therefore, deletion of the both
domains must contribute to this activity. The constitutive activity of
Stat92EΔNΔC in vitro is signiﬁcantly robust that it could be used for
RNAi screens to identify enhancers and suppressors of Stat92E
activity, which may have conserved functions in restricting tumori-
genesis in mammals. In addition, the high rate of melanotic tumor
formation observed in clones mis-expressing Stat92EΔNΔC will make
this mutation an extremely useful in vivo reagent as well.
Fig. 7.Model of action of Stat92EΔNΔC and of Stat92ER442. (A) Basal levels of tyrosine phosphorylation of Dome, Hop and/or Stat92E are kept in check by cellular tyrosine phosphatases
(orange Y-PPT). Inactive Stat92EFL:Stat92EΔNΔC dimers exist at low levels in the cytoplasm of unstimulated cells and can bind to the basally-activated phosphorylated receptor via their
intact SH2 domains. Once bound to the activated receptor, these Stat92E proteins are themselves phosphorylated, leading to the formation of activated Stat92EFL:Stat92EΔNΔC dimers that
translocate to thenucleus, bind consensus Stat92E binding elements onDNAandmodulate gene transcription. Possiblemolecularmechanisms underlying thedominant active behavior of
the Stat92EFL:Stat92EΔNΔC dimers. They could (1) stay bound longer to DNA than endogenous dimers; (2) bemore resistant to conformational change to an unphosphorylated dimer; (3)
be more resistant to dephosphorylation by a nuclear tyrosine phosphatase (green Y-PPT) and/or (4) resist export from the nucleus. (B) Homology model of Stat92E based on the
crystallographic structure of a phosphorylated STAT1 dimer bound to DNA (Chen et al., 1998). Arg442 is displayed as spherical space-ﬁlled atoms and contacts DNA in the minor groove
(white arrow). (B’) Zoomof (A). Arg442 is shown in stickﬁgure form. Arg442 appears to be interactingwith a thymine (T, shown in stick ﬁgure form) andwith a cytosine (C, shown as a red
ball) located in theminor groove of the DNA helix. (C) Alignment of the DNA binding domains of Stat5a (S5a), Stat5b (S5b), Stat6 (S6), Stat92E (S92E), Stat1 (S1) and Stat3 (S3). (D) The
optimal DNA binding sites for mammalian STATs 1-6, Stat92E and STA-1.
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is initiated in the ﬁrst place. The model described above predicts that in
the absence of stimulation (1) Stat92E:Stat92EΔNΔC dimers should be
detected, if only at very low levels, and/or (2) Stat92EΔNΔC should be
tyrosine phosphorylated, again if only at very low levels. Unexpectedly
neither result is observed. To rectify these results, we invoke amodel in
which a few activated STAT dimers (in this case Stat92E:Stat92EΔNΔC
dimers) are constantly generated within a cell, and their activity is
quenched by tyrosine phosphatases (Fig. 7A). Although we have not
been able to detect these dimers, we know that this is a plausible model
because treatment of a cell with vanadate, a pan-phosphatase inhibitor,
activates STATs in a ligand-independent manner, presumably by
inhibiting the enzymes that keep their low level of activation in check
(Duff et al., 1997; Sweitzer et al., 1995; Tourkine et al., 1995). We
hypothesize that Stat92E:Stat92EΔNΔC dimers may better evade the
actions of tyrosine phosphatases, resulting in a steady state of increased
STAT signaling in a cell and ultimately leading to sustained, increased
expression of STAT targets and, in certain cell types like the blood,
oncogenesis.
As mentioned above, we also discovered that Stat92E lacking either
theN- or the C- terminus functioned similarly to Stat92EFL. They rescued
the eye/antennal/head phenotypes, as well as the hatching rate, and
they shifted the lethality in either 85C9/85C9 or 397/397 zygotic
mutants. The fact that a transgene encoding a Stat92E lacking the last 36
amino acids could rescue the phenotypes associatedwith homozygosity
for the 397 allele, which is predicted to encode a protein lacking all
amino acids after Trp594, suggests that the transactivation domainof Stat92E does not residue at the C-terminus, since a Stat92EΔC:
Stat92E397 dimer would lack any residue after 724. Alternatively, there
could bemore than one transactivation domain in Stat92E, one at the C-
terminus and the other located elsewhere in the protein. The proteins
encoded by the Stat92E85C9 and Stat92E397 alleles are predicted to have
N-terminal domains (this work and (Silver and Montell, 2001)).
Previous work has shown that two N-termini are required for the
formation of non-phosphorylated dimers, which are the preferred
substrated of receptor/JAK complexes and are required for cytokine-
dependent activation of STAT4 (Chang et al., 2003; Chen et al., 2003;
Murphy et al., 2000; Ota et al., 2004; Shuai et al., 1996). As such, the
single N-terminus present in any potential dimers between Stat92EΔN
and Stat92E85C9 or between Stat92EΔN and Stat92E397 is unlikely to
support dimer formation/activation in Stat92E85C9 and Stat92E397
homozygous mutant cells, respectively.
Our results showing that Stat92EΔN can function like Stat92EFL
differ from those reported by two other groups (Henriksen et al.,
2002; Karsten et al., 2006). The former authors reported that a Stat92E
lacking the ﬁrst 133 residues was generated by transcription of an
alternative promoter in response to pathway activation and acted as
dominant negative in vivo. Mis-expression of their Stat92EΔN
construct in wild type embryos led to the same phenotype as
complete loss of Stat92E: the loss of expression of even-skipped stripes
3, 5 and 7 (Henriksen et al., 2002; Hou et al., 1996). Karsten et al.
reported that mis-expression of a Stat92EΔN protein tagged at the
C-terminal by GFP (Stat92EΔN–GFP) in the embryo abrogated
expression of trachealess, which is also lost in embryos null for the
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2006). The reason for the discrepacy between our and their results is
not clear at present.
Our study is also noteworthy in that it is the ﬁrst analysis of
Stat92E structure-function variants that employs in vivo rescue assays
in a Stat92E homozygous mutant background.We previously reported
that 90% of animals carrying large patches of Stat92E homozygous
mutant tissue in the eye-antennal disc fail to hatch but that these
phenotypes were rescued when these animals expressed a full-length
version of Stat92E in the eye-antennal disc (this study and (Ekas et al.,
2006)). We now show that mis-expression of Stat92EFL in 85C9/85C9
zygotic mutants signiﬁcantly shifted the lethal phase, from embry-
onic/ﬁrst larval instar to third larval instar/early pupa. Currently we
do not understand why the UASP-3HA-Stat92EFL transgene did not
rescue to 85C9/85C9 homozygotes to adulthood, but one possibility is
low expression. Transgenes driven by UASP, which are designed for
expression in the germ-line (Rorth, 1996), are expressed at
signiﬁcantly lower levels than those driven by UAST, which are
expressed in the soma (Brand and Perrimon, 1993), and the levels of
Stat92E required to rescue to 85C9 or 397 zygotic mutants to
adulthood simply might not have been achieved.
We are the ﬁrst to demonstrate that Tyr711 is required for Stat92E
function in vivo, which is consistent with in vitro data that a
substitution of Tyr711 to Phe abolished the ability of Stat92E to bind
DNA (Karsten et al., 2006; Yan et al., 1996). However, we do not
observe a reduction in eye size when we over-express this Stat92E
construct in a wild type ﬂy eye. We believe that this is due to our
inability to over-express this construct at high enough levels to inhibit
the function of endogenous Stat92E. Finally, we have also shown that
an Arg residue is speciﬁcally required at position 442 for Stat92E
function. Our homology model of Stat92E suggests that Arg442 is
involved in DNA binding and may be a recognition element for the
binucleotide TTCnnnGAA in the Stat92E binding site, suggesting that
this interaction may be important for Stat92E recognition of its DNA
target site. The Arg442 of Stat92E is conserved in the C. elegans STAT,
STA-1, and in mammalian STAT2,3,5a,5b and 6. Therefore, it will be
interesting in the future to determine if this residue is also required
for the function of STAT proteins in which this Arg residue is
conserved.
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